Drug safety is a barrier to the discovery and development of new androgen receptor antagonists

  title={Drug safety is a barrier to the discovery and development of new androgen receptor antagonists},
  author={William R. Foster and Bruce D. Car and Hong Shi and Paul C. Levesque and Mary T. Obermeier and Jinping Gan and Joseph C. Arezzo and Stephanie Powlin and Joseph E. Dinchuk and Aaron J. Balog and Mark E. Salvati and Ricardo M Attar and Marco M. Gottardis},
  journal={The Prostate},
Androgen receptor (AR) antagonists are part of the standard of care for prostate cancer. Despite the almost inevitable development of resistance in prostate tumors to AR antagonists, no new AR antagonists have been approved for over a decade. Treatment failure is due in part to mutations that increase activity of AR in response to lower ligand concentrations as well as to mutations that result in AR response to a broader range of ligands. The failure to discover new AR antagonists has occurred… 

Androgen receptor antagonists for prostate cancer therapy.

A concise overview of the clinically available antiandrogens and the experimental AR antagonists that tackle androgen action with a different approach is given.

Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer

A review of 2 AR-targeted agents recently approved by the Food and Drug Administration and 2 direct antagonists, enzalutamide and ARN-509, that induce apoptosis without agonist activity in preclinical models shows great promise for patients with advanced disease.

Second generation androgen receptor antagonists and challenges in prostate cancer treatment

The current state of AR antagonist development is summarized and the emerging challenges of their clinical application and the potential resistance mechanisms are highlighted, which might be addressed by combination therapies or the development of novel AR-targeted therapies.

The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer

The biology of the AR is reviewed, the key aspects of therapy targeting the AR are discussed, the discovery and development of enzalutamide are reviewed, and other novel agents under investigation in clinical trials that target theAR are evaluated.

Enzalutamide: Development from bench to bedside.

Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.

The most recent advances in AR-directed therapies for CRPC, promising new agents under development, cross-resistance, and mechanisms of resistance for the new-generation AR-targeted agents are reviewed.

Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC)

  • T. Penning
  • Biology, Medicine
    The Journal of Steroid Biochemistry and Molecular Biology
  • 2015

Recent discoveries and developments of androgen receptor based therapy for prostate cancer

The main focus of this review is to discuss the discoveries and developments of various therapies for prostate cancer, including several groups of drugs that have sparingly good anti-cancer activities, as well as a similar structure and behaviour.

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

ODM-201 is a potent AR inhibitor that overcomes resistance to AR-targeted therapies by antagonizing both overexpressed and mutated ARs and is currently in a phase 3 trial in CRPC.

Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer

The availability of enzalutamide is put into context with the five other agents that modify survival outcomes in metastatic castration resistant prostate cancer and some of the new challenges confronting the field regarding sequencing and combinations of these agents are discussed.



Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.

In mature rats, BMS-641988 strongly inhibited androgen-dependent growth of the ventral prostate and seminal vesicles and was highly efficacious in the LuCaP 23.1 human prostate xenograft model, inducing stasis throughout the approximately 30-day dosing.

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer.

Mechanisms of androgen-refractory prostate cancer.

When prostate cancer is localized in the prostate, the treatment of choice is prostatectomy or irradiation, however, when the tumor relapses or is already metastatic at diagnosis, therapy is problematic.

Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC).

  • H. ScherT. Beer M. Fleisher
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
MDV3100 is a promising candidate for the treatment of prostate cancer assessed by PSA, imaging, CTC, and time on treatment, and data suggest a dose-response trend and consistency across endpoints.

Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration

To evaluate the pharmacokinetics, tolerability and effect on endocrinology of bicalutamide given as once‐daily monotherapy at doses of >150 mg to patients with locally advanced (M0) or metastatic

Neurosteroid Access to the GABAA Receptor

Neuroactive steroids do not require direct aqueous access to the receptor, and membrane accumulation is required for receptor modulation, according to current views of receptor modulation.

Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers

Issued by the FDA's Center for Drug Evaluation and Research (CDER) in July 2005, this serves as the industry guide for determining the estimated maximum recommended starting dose (MRSD) for initial

Pregnenolone sulfate block of GABAA receptors: mechanism and involvement of a residue in the M2 region of the α subunit

Pregnenolone sulfate is a sulfated neurosteroid which reduces the responses of the γ‐aminobutyric acid A (GABAA) receptor and its actions on single‐channel currents from recombinant GABAA receptors formed from α1, β2 and γ2L subunits are analysed.